Search Videos and More

Showing 145 - 156 of 551 results

Previous| 1... 12 | 13 | 14 ...46 |Next


Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy News

Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy

A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.
Finding New Vulnerabilities in Uterine and Ovarian Cancers News

Finding New Vulnerabilities in Uterine and Ovarian Cancers

Just like humans, cells get stressed, too — especially cancer cells. For decades, Dana-Farber researchers have been characterizing a complex molecular condition in cancer cells known as DNA replication stress.
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds News

Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
2025 American Society of Clinical Oncology (ASCO) Symposium

2025 American Society of Clinical Oncology (ASCO)

ASCO 2025: GU Highlights Symposium

ASCO 2025: GU Highlights

Disparities Research Symposium Focuses on Clinical Trials News

Disparities Research Symposium Focuses on Clinical Trials

Above all else, clinical research is about action – moving promising findings from the lab to patient care. The same can now be said about addressing disparities in clinical trial participation: that such disparities exist is well documented; the question going forward is how to reduce them. 
Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer Document

Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.
Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer - Updated in 2025 Document

Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer - Updated in 2025

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.
Patients With a History of Breast Cancer who Desire Pregnancy Document

Patients With a History of Breast Cancer who Desire Pregnancy

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer News

New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer

Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guideline
Anti-inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence for a Subset of Patients News

Anti-inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence for a Subset of Patients

Review analysis of data from a randomized clinical trial for patients with stage 3 colon cancer
Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis Video

Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis

Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.

Showing 145 - 156 of 551 results

Previous| 1... 12 | 13 | 14 ...46 |Next